MYC inhibitors in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The MYC proto-oncogene's role in cancer, particularly hematologic malignancies, has been recognized for over 40 years.
• MYC deregulation is a hallmark of multiple myeloma (MM), a plasma cell cancer, indicating its therapeutic potential.

Purpose of the Study:

• To review the current therapeutic strategies targeting MYC in multiple myeloma.
• To summarize the clinical testing results of various MYC-targeting compounds.
• To propose future directions for developing and improving MYC-targeted therapies for MM.

Main Methods:

• Literature review of studies on MYC function in cancer.
• Analysis of clinical trial data for MYC inhibitors in multiple myeloma.
• Synthesis of information on the challenges and successes of targeting MYC.

Main Results:

• MYC's significance in malignant transformation, especially in hematologic diseases like MM, is well-established.
• Targeting MYC is difficult due to its structural properties, but direct and indirect inhibition strategies show therapeutic potential.
• Various compounds targeting MYC have been tested in MM clinical settings.

Conclusions:

• Despite challenges, MYC inhibition holds promise for multiple myeloma treatment.
• Continued efforts in drug discovery, repurposing, and redesign are crucial.
• Combining novel MYC-targeting agents with standard care may overcome resistance and improve MM management.